Table 1.
Patient baseline characteristics in the NACT-LG and LG groups.
| NACT-LG (n = 41) | LG (n = 35) | P | |
|---|---|---|---|
| Age (years) | 0.112 | ||
| < 60 | 19 (46.3) | 10 (28.6) | |
| ≥ 60 | 22 (53.7) | 25 (71.4) | |
| Sex | 0.231 | ||
| Male | 32 (78.0) | 23 (65.7) | |
| Female | 9 (22.0) | 12 (34.3) | |
| BMI (kg/m2) | 23.2 ± 1.9 | 22.6 ± 2.8 | 0.238 |
| ECOG PS | 0.760 | ||
| 0 | 26 (63.4) | 21 (60.0) | |
| 1 | 15 (36.6) | 14 (40.0) | |
| Tumor size (cm) | 0.193 | ||
| < 5 | 26 (63.4) | 17 (48.6) | |
| ≥ 5 | 15 (36.6) | 18 (51.4) | |
| Tumor location | 0.187 | ||
| Upper third | 15 (36.6) | 6 (17.1) | |
| Middle third | 14 (34.1) | 14 (40.0) | |
| Lower third | 12 (29.3) | 14 (40.0) | |
| Total | 0 (0) | 1 (2.9) | |
| Borrmann type | 0.117 | ||
| I | 1 (2.4) | 2 (5.7) | |
| II | 7 (17.2) | 1 (2.9) | |
| III | 32 (78.0) | 29 (82.9) | |
| IV | 1 (2.4) | 3 (8.6) | |
| Lauren type | 0.913 | ||
| Diffused | 9 (22.0) | 9 (25.7) | |
| Intestinal | 18 (43.9) | 14 (40.0) | |
| Mixed | 14 (34.1) | 12 (34.3) | |
| cT stage | 0.367 | ||
| T3 | 18 (43.9) | 19 (54.3) | |
| T4 | 23 (56.1) | 16 (45.7) | |
| Chemotherapy cycles | |||
| Preoperative | 4 (3–6) | NA | NA |
| Postoperative | 3 (3–6) | 4 (3–6) | 0.160 |
Fisher’s exact test was used as an alternative to Chi-square test when the number in one of the cells is smaller than 5.
NACT neoadjuvant chemotherapy, LG laparascopic gastrectomy, BMI body mass index, ECOG PS Eastern Clinical Oncology Group performance status, NA not applicable.